Corticotroph Pituitary Carcinoma in a Patient With Lynch Syndrome (LS) and Pituitary Tumors in a Nationwide LS Cohort | Zendy

Daniel Bengtsson | Zendy; Patrick Joost | Zendy; Christos Aravidis | Zendy; Marie Askmalm Stenmark | Zendy; A Bäckman | Zendy; Beatrice Melin | Zendy; Jenny von Salomé | Zendy; Theofanis Zagoras | Zendy; Samuel GebréMedhin | Zendy; Pia Burman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Corticotroph Pituitary Carcinoma in a Patient With Lynch Syndrome (LS) and Pituitary Tumors in a Nationwide LS Cohort

Author(s) -

Daniel Bengtsson,

Patrick Joost,

Christos Aravidis,

Marie Askmalm Stenmark,

A Bäckman,

Beatrice Melin,

Jenny von Salomé,

Theofanis Zagoras,

Samuel GebréMedhin,

Pia Burman

Publication year - 2017

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2017-01401

Subject(s) - medicine , pituitary tumors , lynch syndrome , oncology , germline mutation , cancer , dna mismatch repair , mutation , colorectal cancer , biology , genetics , gene

Germline mutations in MMR genes may contribute to the development and/or the clinical course of pituitary tumors. Because tumors with MMR mutations are susceptible to treatment with immune checkpoint inhibitors, we suggest to actively ask for a family history of LS in the workup of patients with aggressive pituitary tumors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research